Get started
Author

Chiang Li

Cancer Therapy with ß-Lapachone
2002 · Arthur Pardee, You Li, et al. · Current Cancer Drug Targets · 216
Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge
1999 · Sandra S. Cohen, Chiang Li, et al. · Proceedings of the National Academy of Sciences · 90
Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
2015 · Carlos Becerra, Joe Stephenson, et al. · Journal of Clinical Oncology · 30
Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles: A promising approach in liver-specific RNAi delivery
2014 · S. Sajeesh, Tae Yeon Lee, et al. · Journal of Controlled Release · 30
A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies.
2013 · Adrian Langleben, Jeffrey G. Supko, et al. · Journal of Clinical Oncology · 25
The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
2018 · Manish A. Shah, Kohei Shitara, et al. · Journal of Clinical Oncology · 23
Long dsRNA-Mediated RNA Interference and Immunostimulation: A Targeted Delivery Approach Using Polyethyleneimine Based Nano-Carriers
2014 · S. Sajeesh, Tae Yeon Lee, et al. · Molecular Pharmaceutics · 22
A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies.
2014 · Matthew Hitron, Joe Stephenson, et al. · Journal of Clinical Oncology · 19
A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors.
2014 · Derek J. Jonker, Joe Stephenson, et al. · Journal of Clinical Oncology · 19
The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.
2015 · Manish A. Shah, Kei Muro, et al. · Journal of Clinical Oncology · 18
ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells
2007 · Sébastien Jeay, Neru Munshi, et al. · Cancer Research · 18
Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).
2018 · Tanios S. Bekaii-Saab, Alexander Starodub, et al. · Journal of Clinical Oncology · 17
A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).
2017 · Tanios S. Bekaii-Saab, Alexander Starodub, et al. · Journal of Clinical Oncology · 17
CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).
2017 · Axel Grothey, Manish A. Shah, et al. · Journal of Clinical Oncology · 16
Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).
2017 · Johanna C. Bendell, Joleen Marie Hubbard, et al. · Journal of Clinical Oncology · 14
A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors.
2014 · Scott Andrew Laurie, Derek J. Jonker, et al. · Journal of Clinical Oncology · 14
Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).
2017 · Johanna C. Bendell, Bert H. O'Neil, et al. · Journal of Clinical Oncology · 13
A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.
2016 · Carlos Becerra, Fadi S. Braiteh, et al. · Journal of Clinical Oncology · 13
CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
2017 · Tanios S. Bekaii-Saab, Chung-Pin Li, et al. · Journal of Clinical Oncology · 12
Adsorptive stripping voltammetry of some trace elements in biological samples. I. Cadmium and zinc
1988 · Chiang Li, Bruce D. James, et al. · Microchimica Acta · 12
BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer.
2017 · Tim Larson, Waldo Feliu Ortuzar, et al. · Journal of Clinical Oncology · 11
A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.
2016 · Tanios S. Bekaii-Saab, Sameh Mikhail, et al. · Journal of Clinical Oncology · 11
Abstract 4777: Cancer stemness and resistance: Napabucasin (BBI-608) sensitizes stemness-high cancer cells to Paclitaxel by inhibiting the STAT3-MUC1 pathway
2017 · Harry A. Rogoff, Juying Li, et al. · Cancer Research · 9
A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.
2017 · Gregory Michael Cote, William Jeffery Edenfield, et al. · Journal of Clinical Oncology · 8
ARQ 197, a small molecule inhibitor of c-met, prevents bone metastasis in a humanized mouse model of breast cancer
2007 · K. C. Anderson, Chiang Li, et al. · Molecular Cancer Therapeutics · 8
Works count: 48
Citation count: 772
H-index: 14
I10-index: 22
Year
Topic
Type